UBS resumes coverage of IQVIA Holdings stock with USD 345.00 target

Published on 10/01/2026 at 16:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 4.37 billion, up 8.70 percent year over year. IQVIA Holdings stock costs EUR 235.70 on October 1, 2026 after EUR 237.30.

Pop-Art-Comic eines Pharma-Wissenschaftler-Superhelden mit Datenanalyse-Schaubild und Halbton-Muster — IQVIA Holdings Pharmawissenschaftler US46266C1053 als farbiger Pop Art Comic Held mit Datenanalyse Chart in Siegerpose, Illustration mit AI erstellt.

IQVIA Holdings (ISIN US46266C1053) received a USD 345.00 price target when UBS resumed coverage with a Buy rating on September 30, 2026, according to Investing.com. The call puts bookings and the outlook for clinical research demand at the center of the current valuation debate.

UBS sees bookings improving

UBS said book-to-bill could continue climbing above 1.22x and argued that IQVIA's data infrastructure may help it capture artificial intelligence cost savings, Investing.com reported on September 30, 2026. The same report said biotech funding was up 87.00 percent year over year on a trailing-twelve-month basis, while pharmaceutical research and development was expected to grow 5.20 percent annually over the long term.

The valuation case is therefore tied to operating leverage rather than only to a market multiple. UBS said IQVIA could gain share from competitors, while its estimates assume revenue growth of 4.00 percent to 5.00 percent and annual margin expansion of 0 to 15 basis points through 2036.

Second-quarter figures set the baseline

IQVIA reported second-quarter 2026 adjusted earnings per share of USD 3.15 against a USD 3.04 consensus estimate, while revenue reached USD 4.37 billion versus USD 4.30 billion expected, according to Investing.com on September 28, 2026. Revenue was up 8.70 percent year over year, giving the company a quantified operating foundation for the new analyst optimism.

IQVIA also set fiscal 2026 adjusted earnings-per-share guidance at USD 12.80 to USD 13.00. The company separately announced a USD 2.0 billion senior-notes offering due in 2034 on September 9, 2026, with proceeds intended partly to redeem debt due in 2026, according to IQVIA.

Stock remains below the yearly high

IQVIA has a market capitalization of USD 43.7 billion as of October 1, 2026. Its primary exchange is the NYSE, where the finance quote showed a USD 154.50 to USD 277.40 52-week range on October 1, 2026, leaving the USD 265.78 primary-exchange quote below the yearly high while the euro reference price reflects a separate German trading venue.

For investors, the key contrast is clear: UBS targets bookings-led growth, while the second-quarter operating picture already combines revenue growth with earnings above consensus. The next earnings date is October 26, 2026.

IQVIA stock slips against prior close

IQVIA stock was trading at EUR 235.70 at Lang & Schwarz on October 1, 2026 at 4:10 p.m. CEST, down 0.67 percent versus the prior close of EUR 237.30 on September 30, 2026. The further course of trading is shown by the continuously updated real-time quote of IQVIA Holdings stock.